# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: James Madison (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN007-SYN-TD
- Date: 1774-09-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Josiah Pembroke-Achebe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Three-month review after completing psychotherapy. **S**

## History of present illness

Mr. Madison returns after completing all twelve psychotherapy sessions. Since his preventive visit ten weeks ago he has had one event, during his stomach illness five weeks ago, and none since; he recognizes the warning feeling earlier and uses his grounding steps. He has taken sertraline 50 mg each morning for fifteen weeks, apart from two days missed when he was vomiting; he has no side effects now. The nurse telephone check planned two weeks after starting sertraline did not take place. His mood is steadier and he worries less; he sat the law school admission test last week with extra breaks and felt he did himself justice. He has gone back to evening civic meetings with a friend who knows the first-aid plan. He has not driven and asks when he may. He has had no thoughts of death or self-harm, and the rifle remains locked. **S**

| Element | Detail |
|---|---|
| Events | One in ten weeks, during an acute illness; none for five weeks |
| Psychotherapy | Twelve of twelve sessions completed; relapse-prevention plan written |
| Sertraline | 50 mg for fifteen weeks; no side effects now |
| PHQ-9 and GAD-7 | 6 and 7 |
| Driving | Not driving; asks when he may |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight 55.2 kg; well |
| Gastrointestinal | Negative | Gastroenteritis resolved within four days |
| Neurological | Negative | No events for five weeks |
| Psychiatric | Positive | Mood steadier; some worry about results; no suicidal thoughts |

4 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, half a tablet (25 mg) each morning for one week, then one tablet (50 mg) each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/70 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 55.2 kg; BMI 19.6 kg/m². All vital signs are synthetic.

PHQ-9: 6; GAD-7: 7. All results are synthetic.

## Change since baseline

- PHQ-9: 13 at baseline, 6 at this visit **S**
- GAD-7: 14 at baseline, 7 at this visit **S**

## Immunizations given today

- Influenza vaccine, 1774-1775 season **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, brighter |
| Mental status | Mood "steadier than in years"; affect full; logical; no suicidal ideation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Functional/dissociative seizures** (F44.5). Events have fallen from two or three a month to one in ten weeks, during an acute illness, and none for five weeks, after a full course of CBT-informed psychotherapy. Not on any antiseizure medicine. **S**
   - Keep the relapse-prevention plan and diary; booster psychotherapy sessions are available.
   - Driving: may resume once he has been free of events for three months, in about eight weeks, if he stays event-free, with the neurologist's agreement and in line with state licensing rules; he agrees not to drive until then.
   - Influenza vaccine today; COVID-19 vaccine at his pharmacy this month.
2. **Major depressive disorder, single episode, moderate** (F32.1). PHQ-9 6, down from 13 (54 percent): a response, not yet remission; item 9 scored 0. **S**
   - Continue sertraline 50 mg; consider 75 mg if the PHQ-9 is not below 5 at the next visit.
   - Continue for at least six to twelve months after remission.
   - Safety plan reviewed; 988 Suicide & Crisis Lifeline confirmed.
3. **Generalized anxiety disorder** (F41.1). GAD-7 7, down from 14. **S**
   - Continue sertraline and the coping skills from therapy.
4. **Acute viral gastroenteritis** (A08.4). Resolved. **S**
   - No further action.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 6, down from 13 (54 percent); item 9 scored 0 |
| Survey | PHQ-9 at least monthly during acute treatment | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Deferred | Missed: after the preventive visit, no PHQ-9 was recorded for ten weeks; the sick visit in between did not repeat it. No harm: no suicidal thoughts were reported at the sick visit, and today's score shows a response. Corrective action: a monthly PHQ-9 by the care manager, by telephone or the patient portal, between visits until remission |
| Survey | GAD-7 | With the PHQ-9 when anxiety accompanies depression | Completed today | 7, down from 14 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior; rifle locked; protective factors stronger |
| Examination | Event diary: frequency, duration, triggers, warning sensations, and injuries | Every visit | Completed today | One event in ten weeks, during gastroenteritis; none for five weeks |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Deferred | Missed: the nurse telephone check planned two weeks after starting sertraline was not made. Tolerability was first reviewed at the preventive visit five weeks after the start, when he reported mild nausea in the first week that had settled. No harm: no side effects now and no suicidal thoughts at any contact. Corrective action: the care manager now books the two-week call at the visit where an antidepressant is started or changed |
| Medication safety | Adherence and adverse effects | Every visit during active treatment | Completed today | Two doses missed during vomiting; otherwise no missed doses; no side effects |
| Medication safety | Antiseizure medicines | Every visit | Not indicated | None needed; emergency card in place |
| Referral | CBT-informed psychotherapy for functional seizures | Weekly during the course | Completed today | Course completed; relapse-prevention plan written |
| Self-management | Driving | Every visit until cleared | Completed today | Five weeks free of events; may resume after three months, about eight weeks from now, with the neurologist's agreement |
| Self-management | Sleep, studies, and first-aid plan | Every visit | Completed today | About seven hours of sleep; admission test taken with accommodations; back at civic meetings |
| Laboratory | Lithium, anticonvulsant mood-stabilizer, or antipsychotic monitoring | Only on those drugs | Not indicated | Not taking any; no bipolar features |

## Goal progress

- Cause of the episodes established by the second visit. Outcome by 1774-04-30: Functional/dissociative seizures documented by video-EEG; epilepsy and syncope excluded. **S**
- Antiseizure medicine stopped safely. Outcome by 1774-06-11: Levetiracetam tapered over three weeks and stopped, with no change in events and less irritability. **S**
- Events reduced by at least half, then free of events for three months. In progress; target 1774-12-31. **S**
- Depression and anxiety improved by at least 50 percent (PHQ-9 and GAD-7). In progress; target 1774-12-31. **S**
- No suicidal thoughts. In progress; target 1774-12-31. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- Hingray C, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia 2025;66(11):4162-4182 (PMID 40884444) (2025), International League Against Epilepsy
- LaFrance WC Jr, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry 2014;71(9):997-1005 (PMID 24989152) (2014), JAMA Psychiatry
- Goldstein LH, et al. Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. Lancet Psychiatry 2020;7(6):491-505 (PMID 32445688) (2020), Lancet Psychiatry
- Tolchin B, et al. Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement. Neurology 2025;104(7):e213459 (PMID 40073306) (2025), American Academy of Neurology, American Epilepsy Society, and Epilepsy Foundation of America
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Review in six to eight weeks, when the three-month event-free interval is reached, for driving; monthly PHQ-9 by the care manager. **S**

